HOXA9 inhibits migration of lung cancer cells and its hypermethylation is associated with recurrence in non-small cell lung cancer

Molecular Carcinogenesis

Volumn 54, Issue S1, 2015, Pages E72-E80

  Hwang, Jung Ah ^a   Lee, Bo Bin ^b   Kim, Yujin ^b   Hong, Seung Hyun ^a   Kim, Young Ho ^b   Han, Joungho ^b   Shim, Young Mog ^b   Yoon, Chae Yeong ^a   Lee, Yeon Su ^a   Kim, Duk Hwan ^b,c  

^a National Cancer Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c NONE

Author keywords

HOXA9; Hypermethylation; Lung cancer; Migration; Recurrence

Indexed keywords

FORMALDEHYDE; KI 67 ANTIGEN; TRANSCRIPTION FACTOR HOXA9; HOMEODOMAIN PROTEIN; PRIMER DNA;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CELL MIGRATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER CELL LINE; MALE; METHYLATION; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; TRANSIENT TRANSFECTION; TUMOR VOLUME; AGED; DNA METHYLATION; GENETICS; LUNG TUMOR; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR CELL LINE; TUMOR RECURRENCE;

AGED; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA METHYLATION; DNA PRIMERS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 84931092537     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22180     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2005; 58:71-96.
2. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006; 66:4049-4054.
3. Krumlauf R. Hox genes in vertebrate development. Cell 1994; 78:191-201.
4. Rauch T, Wang Z, Zhang X, et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 2007; 104:5527-5532.
5. Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006; 16:383-393.
6. Nelson HH, Marsit CJ, Christensen BC, et al. Key epigenetic changes associated with lung cancer development: Results from dense methylation array profiling. Epigenetics 2012; 7:559-566.
7. Olaussen KA, Soria JC, Park YW, et al. Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC. Eur J Cancer 2002; 41:2112-2119.
8. Selamat SA, Galler JS, Joshi AD, et al. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS ONE 2011; 6:e21443.
9. Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol 2013; 31:4140-4147.
10. Kim JS, Lee H, Kim H, et al. Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer. J Clin Oncol 2004; 22:3443-3450.
11. Edge SB, Byrd DR, Compton CC, Fritz AF, Greene FL, Trotti A, editors. Lung AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010. p. 253-270.
12. Hwang JA, Kim Y, Hong SH, et al. Epigenetic inactivation of heparan sulfate (glucosamine) 3-o-sulfotransferase 2 in lung cancer and its role in tumorigenesis. PLoS ONE 2013; 8:e79634.
13. Bruhl T, Urbich C, Aicher D, Acker-Palmer A, Zeiher AM, Dimmeler S. Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ Res 2004; 94:743-751.
14. Kim JS, Han J, Shim YM, Park J, Kim DH. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer 2005; 104:1825-1833.
15. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-9826.
16. Kishida Y, Natsume A, Kondo Y, et al. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 2012; 33:436-441.
17. Reinert T, Borre M, Christiansen A, Hermann GG, Ørntoft TF, Dyrskjøt L. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS ONE 2012; 7:e46297.
18. Montavon C, Gloss BS, Warton K, et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 2012; 124:582-588.
19. Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004; 96:1208-1219.
20. Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 2008; 9:676-682.
21. Rudin CM, Avila-Tang E, Harris CC, et al. Lung cancer in never smokers: Molecular profiles and therapeutic implications. Clin Cancer Res 2009; 15:5646-5661.
22. Yano T, Miura N, Takenaka T, et al. Never-smoking nonsmall cell lung cancer as a separate entity: Clinicopathologic features and survival. Cancer 2008; 113:1012-1018.
23. Nakamura T, Largaespada DA, Lee MP, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 1996; 12:154-158.
24. Bandyopadhyay S, Ashraf MZ, Daher P, Howe PH, DiCorleto PE. HOXA9 participates in the transcriptional activation of E-selectin in endothelial cells. Mol Cell Biol 2007; 27:4207-4216.
25. Costa BM, Smith JS, Chen Y, et al. Reversing HOXA9 oncogene activation by PI3K inhibition: Epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res 2010; 70:453-462.
26. Gilbert PM, Mouw JK, Unger MA, et al. HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest 2010; 120:1535-1550.
27. Plowright L, Harrington KJ, Pandha HS, Morgan R. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer 2009; 100:470-475.
28. Moens CB, Selleri L. Hox cofactors in vertebrate development. Dev Biol 2006; 291:193-206.